Open access
Jul 2026
TARGETED THERAPY AND IMMUNOTHERAPY IN COMBINED ANAPLASTIC AND PAPILLARY THYROID CARCINOMA WITH BRAF V600E MUTATION AND PD-L1 EXPRESSION: A CLINICAL CASE
Targeted therapy demonstrates temporary efficacy in anaplastic thyroid carcinoma; however, the development of resistance and the aggressive nature of the disease significantly limit long-term treatment outcomes.
N. Sloneva, I. Turkpenova, D. Dubchev
· Eurasian Journal of Oncology... · 0 citations